Emergent BioSolutions Inc. (NYSE:EBS) and Valneva SE (Euronext Paris:VLA) today announced the initiation of a Phase 1 clinical trial in the U.S. to evaluate the safety and immunogenicity of VLA1601, their vaccine candidate against Zika virus.
{iframe}https://globenewswire.com/news-release/2018/02/26/1387679/0/en/Emergent-BioSolutions-and-Valneva-Initiate-Phase-1-Clinical-Study-to-Evaluate-Vaccine-Candidate-Against-Zika-Virus.html{/iframe}